USP1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
USP1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy was generated using PatSnap Life Sciences MCP Servers. Target & Disease MCP contributed the biology and disease context, while Clinical Trials MCP contributed validation evidence and clinical competition signals.
Why this report exists: it shows how AI agents can use PatSnap MCP data to produce target evaluation workflows covering biology, validation, competition, IP, and R&D recommendation. Explore PatSnap Life Sciences MCP Servers for AI agents.
Executive Summary
This USP1 Target Evaluation Report is generated from PatSnap MCP data. USP1 is an early but strategically important DDR target for HRD and BRCA-mutant tumors, especially in combination with PARP inhibition or platinum chemotherapy.
Target
USP1
UniProt O94782
Drug Count
49
45 development-stage assets
Trials
6
USP1 solid-tumor trials retrieved by Clinical Trials MCP
Results
1
Clinical Trials MCP result records
Target Attractiveness Snapshot
Biology
Target & Disease MCP describes USP1 as a deubiquitinase that removes ubiquitin from FANCD2 and PCNA and requires WDR48 for high activity.
Disease Context
Clinical development is focused on HRR-mutated, BRCA1/2-mutant, HRD-positive, and advanced solid tumor populations.
Strategy
Treat USP1 as an early precision-DDR opportunity and build around HRR selection and PARP/platinum combinations.
Overall Target Evaluation Score: 72/100
- Biology: Mechanistic biology in FANCD2 and PCNA repair pathways is clear.
- Clinical validation: Clinical Trials MCP returned 6 trials and 1 result record.
- Competition: Competition is emerging, with several early Phase 1/2 programs.
- White space: White space remains in HRR biomarker definition and rational combinations.
Biology and Disease Rationale
USP1 negatively regulates DNA damage repair by deubiquitinating FANCD2 and participates in PCNA-mediated translesion synthesis by deubiquitinating monoubiquitinated PCNA. Target & Disease MCP also notes that USP1 has little activity alone and depends on WDR48, which may matter for selectivity and biomarker design.
Clinical Trials MCP identified ASN-3186, HSK39775, XL309 / ISM3091, SIM0501, and TNG348 programs. TNG348 specifically tested USP1 inhibition alone and with a PARP inhibitor in BRCA1/2-mutant or HRD-positive solid tumors, although it was terminated.
Explore PatSnap Life Sciences MCP Servers for AI agents
Validation and Clinical Competition
| First-in-human signal | KSQ-4279 Phase 1 in advanced solid tumors enriched for deleterious HRR mutations was indexed as positive. |
| PARP-combination rationale | TNG348 and KSQ-4279 studies explicitly include PARP inhibitor combinations. |
| Pipeline breadth | ASN-3186, HSK39775 and XL309 show multiple entrants despite early stage. |
| Clinical risk | SIM0501 and TNG348 termination records indicate this class still has execution risk. |
IP and Competitive Strategy
USP1 IP should cover USP1/WDR48 inhibition, FANCD2 and PCNA pathway biomarkers, HRR mutation selection, PARP or platinum combinations, and resistance after PARP therapy.
Recommendation
USP1 is a promising early DDR target. Best development should stay tightly linked to HRD biology and prove additive value over existing PARP/platinum strategies.
Bottom line: This USP1 Target Evaluation Report is generated from PatSnap MCP data. USP1 is an early but strategically important DDR target for HRD and BRCA-mutant tumors, especially in combination with PARP inhibition or platinum chemotherapy.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
